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Abstract 
 
 
 
 Staphylococcus aureus nasal carriage among patients on 
hemodialysis is considered a risk factor for endogenous S. aureus vascular-
access infection. During the period from May 2004 to January 2005, 99 end 
stage renal disease patients at Ramallah hospital, Augusta Victoria hospital, 
and Alia hospital  were screened for nasal carriage of S. aureus and 41 
(41.4%) were colonized by S. aureus . For the follow-up of the nasal 
carriage pattern, periodic nasal swabs were obtained and three S. aureus 
nasal carriage pattern have been distinguished: persistent (17.17%), 
intermittent (24.24%), and non-carrier (58.6%). Most of the S. aureus 
clinical isolates possessed capsular polysaccharides of multiple serological 
types, (48.15%) possessed a polysaccharide type 5 capsule, (33.33%) 
possessed a polysaccharide type 8 capsule,   and the remaining (18.52%) had 
capsular polysaccharide that were not typed by type 5 or type 8 antibodies. 
MRSA isolates were more likely to have different capsular polysaccharides 
types: CP5, CP8, and non 5 nor 8 capsular polysaccharides. 
 
 VII
 The antibiotic susceptibility testing revealed that the S. aureus strains 
fitted in 14 antibiogram types, with the type showing resistance only to 
Penicilin and Ampicillin prevalent in 48 out of 81 isolates ( 59.25%). 
 
For better understanding of the immune response in ESRD patients to 
nasal S. aureus, we used enzyme-immuno linked assay to measure the 
concentration of anti-CP5 and anti-CP8 antibody. The heterogeneity of the 
antibody level among ESRD patients in both carrier and non-carrier 
emphasized that there is no correlation between nasal carriage of S. aureus 
and human immune response, and that high antibody concentration is not 
positively related to S. aureus nasal carriage in ESRD patients.  
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Chapter One 
Introduction 
 
Staphylococcus aureus 
 Staphylococcus aureus is the most common cause of serious hospital-
acquired infections, including blood stream infections and post-operative 
wound infections. The increased resistance of S. aureus to many different 
antibiotics is a growing source of concern in the medical community. 
Staphylococcus aureus  is a gram-positive facultative anaerobic, non-
sporulating, non-motile, catalase positive, oxidase-negative and coagulase-
positive cocci arranged in clusters resembling grapes. It is often -hemolytic 
and forms large yellow colonies on blood agar and it grows well at a 
temperature range from 15˚C to 45˚C and at a salt (NaCl) concentration as 
high as 15%. Based on laboratory investigations S. aureus is distinguished 
from the other staphylococcal species on the basis of the gold pigmentation 
of colonies and positive results of coagulase, mannitol fermentation, and 
deoxyribonyclease tests   (Lowy, 1998). 
 The cell wall of S. aureus is a typical gram positive cell wall with 
thick and highly cross-linked peptidoglycan layer. The peptidoglycan 
consists of glycogen strands of N-acetyglucosamine and N-acetylmuranic 
acid disaccharides cross linked by tetra-peptides consisting of L-alanine, D-
 
glutanime, and D-alanine and L-lysine that are attached to the N-
acetylmuramic acid ( Geisbrecht er al., 1998). Another common feature in 
the cell wall is teichoic acid which consists of almost 50% of total mass of 
the cell wall. Teichoic acid functions in the specific adherence of S. aureus 
to mucosal surfaces ( Elmer et al., 5th ed) 
 Staphylococcus aureus has a number of virulence factors that are 
coded with a complicated coordination between several regulatory systems. 
For the majority of diseases caused by S. aureus, it is difficult to determine 
precisely the role of each given factor. However these virulence factors are 
involved in adhesion, host defense evasion and tissue penetration. Such 
virulence factors of S. aureus include proteins, toxins and capsular 
polysaccharides. Fibrinogen-binding protein (FBP) and collagen binding 
protein are among S. aureus surface proteins, named as microbial-surface 
components  recognizing adhesive matrix molecules (MSCRAMN) of 
human endothelial fibronectin ( Lowy, 1998). The attachments of FBP to 
host endothelial fibronectin is  considered necessary for efficient 
internalization of S. aureus into epithelial cells and phagocytes, even without 
the need for S. aureus specific receptors (Sinha et al., 2000). Protein A is 
another surface protein of S. aureus that has the ability to interfere with 
opsonization and ingestion of the bacteria by polymorphonuclear cells 
 
(PMNs), as it binds to the Fc region of the immunoglobulin IgG molecules 
thus preventing opsonization (Elmer et al., 5th ed ).  
  Staphylococcus aureus produces a variety of exoproteins or enzymes 
that contribute to S. aureus ability to cause disease by either degrading the 
host tissue to use it as nutrient needed for growth of the bacteria itself, or 
facilitate the penetration of S. aureus deeper into host tissue. Such enzymes 
include hemolysins (, , , and ). -hemolysin has a lysing effect on 
human PMN cells and red blood cells (RBC) by forming a pore in the cell 
membrane, thus allowing the efflux of Potassium (K+)and influx of Sodium 
(Na+) and Calcium (Ca++), causing osmotic swelling and rupture of the 
cells (Dinges et al., 2000). Fibrinolysins, Hyaluronidase and Lipase are also 
among S. aureus enzymes that allow and facilitate the spread of the bacteria 
to adjacent areas by the break down of fibrin clot and hydrolysis of 
intracellular matrix of mucopolysaccharides (Elmer et al., 5th ed ) 
 Staphylococcus aureus produce a wide variety of toxins either 
exotoxins or endotoxins that aid in the pathogenesis of S. aureus. Toxic-
shock syndrome-toxin 1(TSST-1) is one of the exotoxins of S. aureus that 
cause toxic-shock syndrome characterized by hypotension, 
hypoalbuminemia and edema. Staphylococcal food poisoning (SFP) is a 
form of gastroenteritis that results from the ingestion of one of the S. aureus 
 	
enterotoxins (SEs) on food contaminated with S. aureus (Dinges et al., 
2000). 
  
Capsular polysaccharide of Staphylococcus aurus  
Bacterial capsular polysaccharides (CP) are carbohydrates polymers 
made up of a  repeating saccharides units. Most S. aureus strains produce 
external capsules that were first described in 1931. Eleven antigenically 
distinct capsular polysaccharides are recognized (Karakawa et al., 1988). 
Among these eleven capsular serotypes capsular type 5 and 8 predominate 
among clinical isolates of S. aureus (Naw’as, 1998; M Roghmann, 2005). 
Any other S. aureus bacteria that do not react with antibodies to capsular 
type1, capsular type 2, capsular type 5 and capsular type 8 are called non-
typeable (O’Riordan and Lee, 2004). The predominance of capsular type 5 
or 8 among human isolates of S. aureus varies form one study to another 
(Essawi, 1998; Roghmann, 2005). 
 Based on biochemical characteristics of the capsular polysaccharides, 
both capsular  type 5 and type 8 are very similar to each other according to 
their back bone structure, but serologically these two capsular 
polysaccharide are serotype specific (O’Riordan and Lee, 2004), and there is 
no immunological cross-reactivity between them as each of them can 
 

produce specific antibodies that are effective in inducing opsonophagocytic 
killing of S. aureus by leukocytes. This is a proved evidence that capsular 
polysaccharides of S. aureus are associated with host immunity to the 
organism (Karakawa et al., 1988). 
 The expression of capsular polysaccharide type 5 and type 8 by S. 
aureus in vitro is affected by both environmental and bacterial culture 
conditions. Staphylococcus aureus  grown on solid agar media, in glucose 
containing media –as carbon source under Oxygen supply – or under iron 
limitation, will produce higher concentration of capsular polysaccharide than 
bacteria grown in broth medium, or grown on artificial culture media 
(Thakker, 1998; Poutral,1995; Lee, 1993). Carbon dioxide (CO2) acts as a 
down regulator for CP type 5 and CP type 8 expression, as growth of S. 
aureus with 5% CO2 causes a decrease in both capsular polysaccharide 5 and 
capsular polysaccharide 8 expression (Herbert al., 2001). 
 Although capsular type 5 and type 8 S. aureus strains produce smaller 
amounts of capsules compared to type 1 and type 2 strains (O’Riordan and 
Lee, 2004), still capsular type 5 and type 8 play very important role in the 
pathogenesis of S. aureus as they specifically bind to human cells, including 
epithelial cells, endothelial cells and monocytes in a dose and calcium-
dependent manner. As a result this interaction between S. aureus capsular 
 
polysaccharide and host cells is needed for initiation of S. aureus invasion of 
the cells (Soel et al., 1995). The role of capsular type 5  in S. aureus 
virulence has been proved in 1998 when the bacteria with high concentration 
of capsular type 5 were more virulent than mutant strains defective in 
capsular type 5 expression (Thakker et al., 1998). In 2002 it was also proved 
that over production of capsular type 8 caused the persistence of capsular 
polysacchariede positive bacteria in the blood stream, liver and the spleen of 
bacteremia infected experiment mouse (Luong and Lee, 2002). 
 The mechanism of antiphagocytic ability of S. aureus capsular type 5 
and type 8 is based on its ability to inhibit complement mediated 
opsonization. Both capsular type 5 and type 8 mask or cover C3 fragments 
attached to the bacterial cell wall preventing it from binding to the 
complement receptors of the phagocytic cells (Cunnion et al., 2001). This 
was confirmed in the year 2003 when the presence of anti-capsular 
antibodies during complement activation improved the recognition of C3 
fragments bound to  positive S. aureus by complement receptors even when 
the number of C3 molecules is not that high (Cunnion et al 2003). 
 
 
 
 
 
 
Methicillin Resistant Staphylococcus aureus 
 
Methicillin – resistant S. aureus ( MRSA) is an important pathogen,  
and is a major cause of nosocomial infections. Methicillin resistant S. aureus 
is common in many areas of the world, with different prevalence  rates  from 
one geographic region to another,   or even from one section to another of 
one hospital (Fluit et al., 2001). Methicillin resistant S. aureus is primarily 
mediated by the mecA gene that encodes for penicillin- binding protein 2a 
(PBP2a), which reduces the binding affinity for all beta lactam antibiotics 
(Warren et al., 2004). There is no mecA homolog in susceptible strains. Both 
susceptible and resistant strains of S. aureus produce four major PBPs: 
PBPs1, 2, 3, and 4. Penicillin-binding proteins 1, 2, and 3 that have high 
affinity for most -lactam antibiotics are essential for cell growth and for the 
survival of susceptible strains, and binding of -lactams by these PBPs is 
lethal. In methicillin-resistant cells, PBPs 2a with its low affinity for binding 
-lactam antibiotics, can substitute for the essential functions of high-affinity 
PBPs at concentrations of antibiotics that are otherwise lethal (Chambers, 
1997). Nasal colonization of MRSA has been shown to be a risk factor for 
nosocomial infections ( Kluytmans, 1997; Watanable, 2000), as well as 
community-acquired infections. In recent years, community acquired MRSA 
infections have been emerging as a world wide problem (Akram et al., 
 
1998), that could be transmitted from the hospital to the community through 
discharged patients, or even health care workers (Liang, 2005; Charlebois, 
2002). Most cases of community-acquired MRSA infections occur in 
patients with underlying medical conditions and are in frequent contact with 
the health care system, such as hemodialysis patients (Salgado et al., 2003). 
The increase of MRSA infections – nosocomial or community acquired--
created great obstacles for medical professionals, due to failure of treatment 
of the resistant S. aureus. As a result infections caused by MRSA are usually 
treated with Vancomycin. Vancomycin is toxic and the emergence of 
Vancomycin-resistant strains of S. aureus first in Japan in 1996 and in the 
united states, caused great concern that such resistance could result in high 
mortality and morbidity rates (Smith et al., 1999) 
 
 
Carriage of Staphylococcus aureus 
 Humans are natural reservoir of S. aureus that colonizes skin and 
mucus membranes of healthy people. Usually S. aureus colonizes the moist 
squamous epithelial cells of the human nares (Cole et al., 2001). 
Staphylococcus aureus nasal carriage has been studied extensively in both 
patients and healthy individuals (Kluytmans, 1997; Cole, 2001; 
VandenBergh, 1999; Chapoutot, 1999; Ahmed, 1998; Luzer, 1990). The 
 
nasal carriage of S. aureus in healthy adult population has been described to 
fall into three patterns: persistent carriage approximately 20%, intermittent 
carriage 60%, and non carriage 20% ( Kluytmans et al., 1997). The criteria 
used to identify these carriage patterns have varied from one study to another 
depending on the number of nasal specimen cultures that are done, the 
follow-up period, and the interpretation of data (VandenBergh et al., 1999) 
The typing of S. aureus strains isolated from individuals identified as 
persistent carrier showed that almost all stable carrier were persistently 
infected with the same strain of S. aureus and that changes in the strain by 
time seldom occurred (Hu et al., 1995). 
 Age of the studied population affects the proportion of nasal carriage, 
as infant carriage rate ranges from 50% during the first eight weeks of life to 
21% by six months of age (Peacock et al., 2003). Very young school 
students have higher nasal rate of S. aureus than older individuals (Liang et 
al., 2005). In addition the health condition of people also affect the 
percentage of carriage of S. aureus. The percent of carriage rate in 
hospitalized , insulin-dependent diabetes, HIV-positive patients, and also in 
those on hemodialysis or peritoneal dialysis is higher than that in healthy 
individuals (Kluytmans, 1997; Chapoutot, 1999; Ahmed, 1998). 
 The ability of S. aureus to adhere to human endothelial cells is 
 
affected by both  human and bacterial factors. The binding of  S. aureus to 
cell-associated mucus is greater than to non mucus coated epithelial cells. 
This binding between S. aureus and human nasal mucus occurs by specific 
adhesion-receptor interactions involving the fibronectin bridging between S. 
aureus fibronectin-binding proteins ( FnBPs) and human cell fibronectin 
receptors that proved to be sufficient for invasion of S. aureus to host cells 
(Shuter, 1996; Sinha, 2000). 
 Human nasal fluid also contributes to the adhesive process of S. 
aureus. Although the nasal fluid from healthy carriers contains both high 
concentration of neutrophil derived peptides that indicates a neutrophil-
mediated host response to S. aureus colonization, and also high 
concentration of anti-microbial peptides secreted in the nose of carriers 
compared to non-carriers, but still the nasal fluid from carriers is defective in 
killing the self nasal isolates of S. aureus, consequently involved in affecting 
the nasal carriage rate (Cole et al., 2001).  
 The anti-microbial activity of nasal fluid of human includes both 
immunoglobulin A (IgA) and immunoglobulin G (IgG). The reduced 
concentration of these anti-microbial substances due to the abnormalities of 
nasal fluid movements across epithelial, results in reduction of the anti-
microbial activity of the nasal secretions, (Cole et al., 1999). Moreover 
 
epithelial cilia continuously transport mucus with particulate matters and 
microbes down the oro-pharynx, where they are swallowed and may result 
in reduction in bacterial concentration. Still in some cases of people having 
thick mucus or ciliary dysmotility a delay in the clearance of the bacteria 
from the airway occurs and  may permit the microbes to adapt to the 
damaging effects of secretions and to recover and resume growth (Cole et 
al., 1999). Capsular polysaccharides expression of S. aureus is negatively 
correlated to the adhesion of the bacteria to the endothelial cells, as the 
induction of CP type 5 results in reduced adhesion of S. aurues (Pohlmann et 
al., 2000).   
 Nasal S. aureus has been identified as a risk factor for hospital-
acquired, as well as community acquired infections. Hospital acquired 
infections are mostly caused by the patient's own nasal S. aureus in surgical 
patients (Ahmed, 1998; Perl, 2002), intensive care unit patients (Eiff, 2001; 
Singh, 2003), patients with peritoneal dialysis (Sewell, 1982; Luzer, 1990), 
hemodialysis patients (Chow et al., 1989), and broncho-pulmonary infected 
patients (Watanabe et al., 2000). 
 The reservoir of S. aureus in hospital infections is not clear, as some 
patients are already colonized with S. aureus at the time of their hospital 
admission, where others become colonized during their stay in the hospital. 
 
Health care workers are assumed to be one of those sources of S. aureus 
transmission to the patients. Medical staff members who are colonized with 
S. aureus (VandenBergh, 1999; Ahmed, 1998; Cespedes, 2002), or have 
direct contact with colonized patients, can contaminate their hands and  
transmit the bacteria to other patients during their daily routine care of the 
patients in the hospitals or other health care centers (Eveillard, 2004; Lee, 
2000; Pittet, 1999). 
 End stage renal disease patients are at risk of acquiring S. aureus 
infections from the hospitals. End Stage Renal Disease (ESRD) is a slow, 
progressive loss of the kidney ultra-filtration capacity, that results in the 
accumulation of metabolic waste products, disturbance of kidney's endocrine 
functions and electrolytes balance. Renal failure could be acute or chronic: 
Acute renal failure is defined as a rapid deterioration in renal function, 
sufficient to result in accumulation of nitrogenous wastes in the body. In 
acute renal failure the kidney has a remarkable capacity to regain function 
following the various forms of acute renal failure. Chronic renal failure is a 
more severe renal injury that is not reversible and leads to progressive 
destruction of nephron mass. The most common causes of this irreversible 
failure are: Glomerulonephritis, tubulointerstitial diseases, diabetic 
nephropathy, and nephrosclerosis. 
 
End Stage Renal Disease is irreversible and fatal if not early detected 
and properly treated through dialysis or transplantation. Kidney 
transplantation is severely limited due to the shortage of suitable donors, the 
incidence of organ transplant rejection, the age, and health of many ESRD 
patients. The majority of patients, therefore, must rely on dialysis for the 
remainder of their lives. 
Dialysis procedures are based on circulating blood on one side of a 
semi-permeable membrane against a physiologic electrolyte solution on the 
other side to remove the accumulated by products. Hemodialysis uses an 
artificial membrane, while peritoneal dialysis uses the peritoneal membrane 
of the abdomen, which is a large membrane rich in blood vessels, to act as a 
filter to eliminate waste products and excess fluid from the blood. Both 
hemodialysis and peritoneal dialysis are the two prevailing methods of 
dialysis. 
Impaired immunity in uremic patients makes them more susceptible to 
infectious processes. Infection can have a major impact on patients with end- 
stage renal disease. Both typical and opportunistic organisms can infect 
patients with end-stage renal disease ( Chi et al., 2004). Because of the need 
for connection between the outside of the body and the blood stream of the 
patient during dialysis sessions, both hemodialysis and peritoneal dialysis 
 	
techniques predispose the patients to such infections. As a result both forms 
of dialysis require strict aseptic technique to reduce such infections, 
especially infections related to non-hematogenous routes that occur by direct 
inoculation of the access site. An effective hand-washing system by  medical 
staff using an antimicrobial agent is superior to ordinary hand washing, and 
reduces the rate of nosocomial infections (Doebbeling, 1992; Pittet, 1999). 
Furthermore the application of Mupirocin three times a week to 
hemodialysis catheter exit sites is associated with a marked reduction in line-
related sepsis and prolongation of catheter survival (Johnson et al., 2002). 
In hemodialysis patients, Staphylococcus aurues constitutes one of the 
major pathogens that is responsible for high morbidity and mortality rate. It 
is the most frequently isolated pathogen at the vascular access site infections 
associated with bacteremia and septicemia (Saxena, 2003; Kluytmans, 
1997). In peritoneal dialysis patients, S. aureus also causes exit site 
infections and peritonitis, both are difficult to treat and may require 
alteration of dialysis therapy ( Luzer et al., 1990).   
The carriage rate of S. aureus in ESRD patients is higher than that of 
healthy individuals or even non-ESRD patients (Kluytmans et al., 1997). It 
is not clearly understood why the ESRD patients have higher carriage rates 
of S. aurues than others. Nasal carriage of S. aureus is considered an 
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important risk factor for ESRD patients treated by hemodialysis and 
peritoneal dialysis. ESRD patients are prone to S. aureus infections more 
frequently than non carrier (Swell, 1982; Chow and Yu, 1989; 1986), due to 
their decreased immunity, the use of prosthetic devices and multiple needle 
puncture that not only break the normal host defense and give direct access 
to sterile body sites, it also provides a site for colonization (Peacock, 2002; 
Saxena, 2003).  End Stage Renal Disease patients with persistent S. aureus 
nasal carriage tends to have colonization with a single phage type (Yu et al., 
1986). In many studies the strains from the nares and the strains causing the 
infection are similar in phage typing and antibiotic profile (Luzar, 1990; 
Swell,1982; Chow and Lu, 1989). 
 As a preventive measurements  nasal S. aureus  can be eliminated  
using intranasal Mupirocin (Perl 2002; Johnson, 2002), or by the use of 
topical antibiotics Polysporin ointment applied to the central venous catheter 
insertion site for hemodialysis patients in whom permanent vascular access 
can not be achieved (Lok et al., 2003). 
 Recently vaccination with S. aureus conjugate vaccine (StaphVax) to   
patients receiving hemodialysis proved to result in partial immunity against 
S. aureus infections for approximately 40 weeks (Shinefield et al., 2002). 
Staphylococcus aureus capsular type 5 and type 8 capsular polysaccharides 
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conjugate vaccines were developed and evaluated for their safety and 
immunogenicity in healthy volunteers (Fattom et al., 1993). Capsular 
polysaccharides of S. aureus alone are poor immunogens, therefore their 
immunogenicity is enhanced by conjugation with recombinant exoprotein A 
that is a nontoxic variant of Pseudomonas auroginosa (Shinefield et al., 
2002). The vaccine was well-tolerated by immunized volunteers and neither 
the conjugates nor the capsular polysaccharides caused significant adverse 
reactions. The antibodies produced as a result of this conjugate vaccine were 
found to be mainly of IgG class immunoglobulin, and were found to mediate 
in vitro opsonophagocytosis of the type-specific S. aureus by human poly-
morphonuclear cells (Fattom et al., 1993). 
 
 
 
 
AIMS OF THE STUDY 
 
 End Stage Renal Disease patients who are S. aureus nasal carriers, are 
at continuous risk of developing infections. Screening ESRD patients 
periodically for nasal carriage of S. aureus and treatment of only those who 
are colonized will lead to better prevention of serious S. aureus infections. 
The aim of this study is to obtain more information on issues related to S. 
aureus nasal carriage in ESRD patients.  
The specific aims of this study were to: 
1 Screen for S. aureus nasal carriage in ESRD patients. 
2 Characterize S. aureus nasal isolates based on capsular 
polysaccharides serotypes. 
3 Study the role of natural carriage of S. aureus or previous 
infections with S. aureus  on anti-CP type 5 and anti-CP type 8 
concentrations  in ESRD patients.  
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Chapter Two 
 
Materials and Methods 
 
Design and data collection 
 The present study was carried out between May 2004 to January 2005. 
The study population consists of three different groups: ESRD patients, 
Non-ESRD patients, and the medical staff. The number of ESRD patients 
enrolled in the study was 99 from three different hospitals: 34 from 
Ramallah Governmental Hospital in Ramallah, 48 from Augusta Victoria 
Hospital (AVH) in Jerusalem, and 17 from Alia Governmental Hospital in 
Hebron. The 25 NESRD patients were from Ramallah hospital. The 18 
medical staff were from the three mentioned hospitals: five from Ramallah 
hospital, five from AVH, and eight from Alia hospital. 
* Verbal consent was obtained from the patients in the presence of 
authorized physician following explanation about the study and its 
objectives, and also authorized access to patients medical records was 
obtained. 
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Collection and processing of the samples 
  Carriage of S. aureus was determined by obtaining nasal swab    
specimens from both anterior nares using sterile dry cotton-wool swabs 
(LAB service S.P.A). The first two swabs were taken at an interval of one 
week apart, the other two swabs were taken at subsequent dialysis sessions 
within about three months . The blood samples were taken on the same day 
with the first nasal swab. Serum samples were then stored at -80˚C for 
further analysis. 
 
Microbiological methods 
 Nasal swabs were inoculated on both 5% sheep blood agar and 
mannitol salt agar MSA (Oxoid). The plates were incubated for 24 hours at 
35˚C and observed for the growth of suspected S. aureus colonies.  
Staphylococcus aureus isolates were identified on the basis of colony 
morphology golden pigmentation of colonies, -hemolytic activity on blood 
agar, fermentation of mannitol, Gram staining, bound slide coagulase test, 
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tube coagulase test (BD BBL), and Deoxyribonuclease (DNase) test. 
Staphylococcus aureus isolates were suspended in 1:1 glycerol and 
thioglycollate broth and stored at -80˚C for further analysis. 
 
Antimicrobial susceptibility testing 
The antimicrobial susceptibility of all isolates of  S. aureus to 
different antimicrobial agents was determined by the disk agar diffusion 
method in accordance with  the National Committee for Clinical Laboratory 
Standards (NCCLS 1993). The following antimicrobial disks and 
concentrations used were: Penicillin (10 U/ml), Oxacillin (1µg/ml), 
Ampicillin (10µg/ml), Tetracycline (30µg/ml), Clindamycin (2µg/ml), 
Vancomycin (30µg/ml), Erythromycin (15µg/ml), and Cefuroxime 
30uµg/ml). The results  were recorded after 18-24 hours of incubation at 
35˚C. A standard strain of S. aureus (ATCC 25923) was used as a control. 
 
Capsular polysaccharides serotyping 
 
Staphylococcus aureus isolates recovered from the study patients  
(ESRD patients) and the controls ( NESRD patients and the medical staff), 
were streaked on blood agar and incubated overnight at 37˚C. The next day,  
a single colony was streaked on modified Columbia agar (Difo laboratories, 
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Detroit, Michigan) supplemented with 0.5% MgCl2 and 1.5% CaCl2 and 
incubated for 24 hours at 37˚C. Several colonies grown on modified 
Colombia agar were suspended in 500 µl of 0.9% sterile saline and tested by 
slide agglutination with rabbit polyclonal antibodies specific to capsular 
polysaccharides type 5 and type 8 provided and standardized by Nabi 
(Rockville, Maryland). Positive agglutination was observed by visible 
clumps within 30 seconds using clean microscopic slide.  
 
Determination of anti- CP type 5 and anti- CP type 8 in the  
sera of the ESRD patients.  
 
Anti-CP type 5 and anti-CP type 8 titers were determined by an 
enzyme-linked immunosorbent assay ( ELISA) as follows. Microtiter plates 
were coated with 100 µl of 1µg/ml of either CP5 or CP8 in PBS , and the 
plates were incubated at room temperature overnight. To eliminate non-
specific adsorption, the antigen ( CP5 or CP8) was blocked by adding 200µl 
of 1% bovine serum albumin (BSA) in PBS to each well for one hour at 
room temperature. The wells were then washed  3 times with  300µl  of  PBS  
containing 0.1% Brij. The patients sera were diluted 1: 300 with PBS-Brij. 
Then 200µl of the diluted sera were added to the appropriate wells; each 
serum sample was two-fold serially diluted down the plate in parallel with 
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reference antibody (anti-CP5 and anti-CP8) and with negative control. The 
reference antibody (anti-CP5and anti-CP8) was pre-diluted 1: 4000. The 
plates were incubated for one hour at 37˚C. The wells were then washed 3 
times with 300µl PBS-Brij. Peroxidase-conjucated goat anti-human IgG 
antibody ( lot 59663 & lot 65774 – Kirkegaard and Perry Laboratories ) was 
diluted in PBS-Brij to 1:10:000. One hundred microliter of the anti-human 
antibody were added to each well. Plates were then incubated at 37˚Cfor one 
hour and then washed 3 times with 300µl of PBS-Brij. One hundred 
microliters of freshly prepared peroxidaze substrate system ( Kirkegaard and 
Perry Laboratories- KPL) prepared as 1:1 mixture of Hydrogen peroxide 
(H2O2) and Tetra methyl benzoate (TMB) were added to each well and the 
plate was incubated for 10 minutes at room temperature. The enzyme-
substrate reaction was stopped by adding 100µl of 1M Phosphoric acid to 
each well. Finally the absorbance was measured at 450nm using ELISA 
reader, and the result for each serum sample was expressed as concentration 
µg/ml.  
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Calculation of antibody concentration 
1- The linear range of both the reference antibody and serum samples 
was defined by visual inspection of  the data. 
2- The cut off value or the minimum optical density (OD) to take into 
account was defined as the mean optical density of the negative 
control plus two standard deviation. 
3- Total optical density (TOD) was calculated for the reference  anti-CP 
and for each serum by multiplying each dilution factor with its OD, 
then the TOD was averaged for the reference anti-CP and each serum 
samples. 
The concentration of anti-CP in each serum sample was calculated 
using the formula: Serum sample TOD X  Reference concentration  = µg/ml 
                                           Reference TOD 
 
Statistical Analysis:  
 
 Descriptive statistics were used to summarize the data. The t-test was 
used for statistical comparisons between anti-CP type 5, anti-CP type 8 
antibody concentration and nasal carriage status in ESRD patients, also 
between nasal carriage and sex, age, and Non-communicable disease state of 
the patients.  
 
 	
Chapter Three 
 
Results 
Screening for S. aureus carriage in ESRD patients and in NESRD 
patients: 
In total, the ESRD patients enrolled in the study were 99 patients, 
males 50.5% and females 49.5%. The age range was from 4-79 years old 
with a median of 50 years for males and 48 years for females. A total of 55 
patients had either Diabetes mellitus or Hypertension or both. Five (5.1%) 
patients had Diabetes mellitus and 36 (36.4%) had Hypertension while 14 
(14.1%) were having both Diabetes mellitus and Hypertension, and 44 
(44.4%) had neither DM nor HTN. The twenty five NESRD patients 
enrolled in the study were 13 (52%) males, 12 (48%) females, 4 (16%) 
diabetes mellitus, 8 (32%) Hypertension, 6 (24%) with both Diabetes 
mellitus and Hypertension,, and 7 (28%) had neither DM nor HTN. 
According to the vascular access type 88 patients had a fistula, 2 had graft, 
and 9 had subclavian as an access. During the study period 18 of the 99 
ESRD patients died ( table 1). 
 Of the 99 patient’s nasal swabs 41 (41.4%) were positive for S. aureus   
and 58 (58.6%) were negative. For the NESRD patients 3 (12%) were 
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positive for S. aureus and 22 (88%) were negative for nasal S. aureus (Table 
2). Seventeen patients (17.17%) of the ESRD patients were persistent 
carrier, 24 patients (24.24%) were intermittent carriers and 58 patients 
(58.6%) were non- S. aureus carrier (Table 3). The carrier index for each 
patient was defined as the number of nasal swab that is positive for S. aureus 
divided by the total number of nasal swab specimen cultures performed for 
that patient. Persistent nasal carrier are those patients with carrier indices of 
0.7 or higher, intermittent carrier are those with carrier indices between 0.1 
and less than 0.7, and non-carriers are those with carrier indices of zero 
(VandenBergh et al., 1999) 
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Table 1.  General characteristics of ESRD  
 
 Male female Graft Fistula Subcla- 
vian 
DM HTN DM+ 
HTN 
Ramallah 20 14 1 33 0 2 13 2 
AVH 20 28 0 39 9 2 22 11 
Alia 10 7 1 16 0 1 1 1 
Total 50 49 2 88 9 5 36 14 
 
ESRD:  End Stage Renal Disease Patients 
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Table 2: Description statistics of nasal carriage of S. aureus 
                in ESRD and NESRD patients. 
 
 ESRD NESRD 
 Number Percent  Number Percent  
Carrier  41 41.4% 3 12% 
Non-carrier  58 58.6% 22 88% 
Total  99 100% 25 100% 
 
ESRD: End Stage Renal Patients 
NESRD: Non-End Stage Renal  Patients 
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Table 3: Descriptive statistics for the nasal carriage pattern of S. aureus 
     In ESRD Patients               
 
 Frequency Percent 
Persistent (P) 17 17.17 % 
Intermittent (I) 24 24.24% 
Non- Carrier (NC) 58 58.6% 
Total  99 100% 
 
 P:    Carriage index  0.70 
  I:     Carriage index 0.1x< 0.70 
             NC: Carriage index = 0 
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Our data showed that there is no significant difference in the percent 
of nasal carriage between the different age-groups. The percent of nasal 
carriage in the age-group  20 was 45.5%, in the age-group 21-40 was 
46.2%, in the age-group 41-60 was 39.5%, and in the elderly group  60 was 
38.5% (Table 4). According to the sex also there was no significant 
difference between males and females, with males 48% and females 34.7% 
(Table 5).   
Screening for S. aureus  nasal carriage in the medical staff showed 
that of the 18 medical staff 5 ( 27.8%) were S. aureus positive nasal carrier. 
 The percent of S. aureus nasal carriage in the ESRD patients showed 
no significant difference between those patients that have non-
communicable disease and those who do not have. NCDs patients had a 
percent of nasal carriage of 41.8%, while the Non NCDs patients had a 
percent of nasal carriage of 40.9% ( Table 6). 
Among the eighty one of nasal S. aureus isolates , the predominant 
capsular type was type 5 with a prevalence of 48.15% ( 39/81) while the 
prevalence of capsular type 8 was 33.33% (27/81).  The remaining 15 
isolates (18.52%) were non-typeabl. Among the persistent carriers the 
prevalence of both capsular type 5 and type  8 was   58.8% (10/17), and 
35.3% (6/17) respectively, and 5.9% (1/17) were non typeable.  
 
 
 
Table 4: Descriptive statistics of  S. aurens  nasal carriage in different  
              age groups in ESRD patients. 
 
  i20 21- 40 41-60 j60 
N % N % N % N % 
Carrier  10 45.5% 6 46.2% 15 39.5% 10 38.5% 
Non-carrier  12 54.5% 7 53.8% 23 60.5% 16 61.5% 
Total 22 100% 13 100% 38 100% 26 100% 
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Table 5: Descriptive statistics of S. aureus nasal  carriage  
                         according to gender of ESRD patients. 
 
        
         
Male Female  
 Number  Percent  Number Percent  
Carrier  24 48% 17 34.7% 
Non- carrier  26 52% 32 65.3% 
Total  50 100% 49 100% 
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Table 6: Descriptive statistics of S. aureus nasal carriage  
                          according to Non-Communicable disease  state of  
                          ESRD patients. 
       
              
 NCD Non NCD(s) 
 Number Percent Number Percent 
Carrier  23 41.8% 18 40.9% 
Non- carrier 32 58.2% 26 59.1% 
Total  55 100% 44 100% 
          
 NCD(s) : Non- communicable disease  
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Capsular typing of the S. aureus isolates recovered from the NESRD 
patients were 33.3% (1/3) have CP type 8 while 66.7% ( 2/3) did not express 
neither type 5 nor type 8 capsule. Most of the isolates from the medical staff 
60% (3/5) have CP type 5 and 40% (2/5) have CP type 8.  
 The antimicrobial susceptibility of the 81 nasal isolates was tested by 
disc-agar diffusion. Table 7 shows the antibiogram types where the majority 
of the nasal isolates (48/81; 59.3%) were of antibiogram type A, resistant 
only to Penicillin and Ampicillin. Table  8   lists the distribution of nasal S. 
aureus isolates by capsular and antibiogram types. The biggest clusters of 
strains is the one showing the capsular type 5 and antibiogram type A 
constituting ( 27/81; 33.3%). 
 The sera obtained from the 99 ESRD patients showed a great 
variability in the levels of both anti-CP5 and anti-CP8 ranging from 1-137.6 
µg/ml, and 3.1-94.2 µg/ml respectively. Their was no significant difference 
in the antibody level when the anti-CP5 and anti-CP8 antibody concentration 
was tested against the nasal carriage status of the patients. Also there was no 
relation between anti-CP5 and anti-CP8 antibody concentration and S. 
aureus type 5 and type 8 CP carriage. By comparing the concentration of our 
patients antibody to that of  a previous study done in 1993 on pre-immunized 
patients, there was a similarity in anti-CP5, CP8 and antibody concentration.  
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Table  7:  Nasal Staphylococcus aureus antibiogram types identified from  
               The ESRD patients                        
type P Am Ox Va Cc E Tet Cxm 
A r r s s s s s s 
B r r s s s s r s 
C r r r s s s s s 
D s s s s s s s s 
E r r s s r s s s 
F r r r s s s r s 
G r r s s s r s s 
H r r r s s s s r 
I r s s s s s s s 
J r r s s r r s s 
K r r s s s r s r 
L r r r s r r s r 
M r r r s s r s s 
N r r s s s s s r 
 
Abbreviations: P, Penicillin ; Am, Ampicillin; Ox, Oxacillin; Va, Vancomycin; Cc, 
Clindamycin; E, Erythromycin; Tet, Tetracycline; Cxm, Cefuroxime; s, susceptible; r, 
resistant.  
 

 
 
 
 
 
 
Table 8:   Nasal Staphylococcus aureus isolates distributed by capsular and  
                antibiogram type 
 
   
 
Antibiogram types Capsular 
type A B C D E F G H I J K L M N Total 
5 27 4 0 1 1 0 1 2 1 1 0 0 0 1 39 
8 12 6 0 2 0 1 4 0 0 0 1 0 1 0 27 
N 9 1 1 1 0 0 0 0 0 1 0 1 0 1 15 
Total 48 11 1 4 1 1 5 2 1 2 1 1 1 2 81 
 
Discussion 
 
 The present study was designed to determine the prevalence of nasal 
S. aureus among (ESRD, NESRD patients, health workers), characterize the 
nasal S. aureus isolates by capsular typing, and evaluate whether nasal 
carriage of S. aureus has an effect on the human immune response. 
 Staphylococcus aureus nasal carriage has been extensively studied in 
patients and in healthy individuals (Kluytmans, 1997; Cespedes, 2002; 
Saxena, 2003). We present here the first study of the prevalence of nasal 
colonization with S. aureus in ESRD patients done in the West Bank of  
Palestine. The result of this study showing that 41.4% of our ESRD patients 
are nasal carriers of S. aureus fit in well with the results obtained from the 
previous surveys that had evaluated the prevalence of nasal carriage of S. 
aureus in hemodialysis patients  range between 30.1%-84.4% (Kluytmans et 
al., 1997). Although these results are in accordance with previous studies, 
still 41.4% in the developing countries is considered high, and efforts should 
be made to reduce this rate. 
 In the present study we identified 17.17% persistent carrier, 24.24% 
intermittent carrier, and 58.6% non carrier over the study period. The 
carriage pattern in our study is considered less than that established in other 
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studies of healthy individuals as 20% of individuals carry S. aureus 
persistently, 60% carry S. aureus intermittently, and 20% are persistently 
free of S. aureus ( non-carrier) (Kluytmans, 1997; VandenBergh, 1999). The 
difference in the reported carriage pattern is postulated to be affected by 
certain obstacles concerning sample collection: as many of our patients died, 
some refused to give one or two of the nasal swabs, others used to take 
antibiotics at the time of sample collection, and few who were lucky to have 
kidney transplant and were excluded from the study. Furthermore in this 
study the 3 months interval between nasal swabs collection may had an 
effect on the nasal carriage pattern of the ESRD patients. Taking of 
antibiotics by the patients may affected the results, since the consumption of 
antibiotics whether oral or topical antibiotics do not eliminate nasal S. 
aureus completely, as a relapse rate of S. aureus nasal carriage occurs after 
the use of such antibiotics (Kluytmans et al., 1997). 
  In this study, male hemodialysis patients has a higher prevalence of 
nasal S. aureus carriage than did female hemodialysis patients (48% Vs 
36.7%). Although there was no statistical significance in nasal carriage rate 
between males and females, a trend can be seen toward higher carriage rate 
in males that may play a role in future exposure to infections.  
 
 Furthermore the elevated S. aureus nasal carriage rate in ESRD 
patients of the age group  20 with 50% positive nasal carriage might be 
related to the close and direct bodily contact between these patients in 
particular those under the age of 10, that facilitate the transmission of S. 
aureus from one patient to another. Accordingly positive S. aureus nasal 
carrier may be considered a reservoir for transmission of S. aureus to the 
surrounding environment and to other people in direct contact with them. In 
addition other risk factors that might affect nasal carriage of S. aureus on our 
target population  could be related to the immuno compromised health state 
of the patients, malnutrition, and the multi- punctures of their body. 
 Polysaccharide capsules are prevalent among S. aureus isolates from 
both commensally and pathogenic sources. Many studies have used the 
capsule polysaccharide typing scheme for typing infectious S. aureus in 
human (Essawi, 1998; Rogman, 2005). For the first time in the West bank of 
Palestine, the capsular polysaccharides typing scheme is used to study the 
distribution of CP types among nasal S. aureus isolates from ESRD patients. 
The majority of S. aureus nasal isolates (80.2%) were as expected and 
comparable with other studies, capsulated by either type 5 or type 8 capsule, 
with prevalence of type 5 (48.2%), (33.33%) of type 8, and (18.52%) non 5 
nor 8 type. 
 
 In our country where antibiotics are freely dispensed over the counter, 
and hospitals lack policies regarding the use of these antibiotics, so using 
capsular typing in conjunction with antibiogram typing could be used as a 
simple, cheap strategy for control of S. aureus infections. 
 Human humoral immune response to S. aureus infections results in a 
variable antibody response against S. aureus cell wall antigens including 
Peptidoglycan (PG), Lipoteichoic acid (LTA), Fibrinogen Binding Protein 
(FBP), and Capsular polysaccharides (CP) (Dryla, 2005; Colque, 2000). The 
anti-staphylococcus antibody produced due to infections do not seem to be 
protective even in healthy people, and even the higher antibody 
concentration in the convalescent state of infection are only transient and 
decrease in level later post infection. Moreover the antibody levels against S. 
aureus do not differentiate significantly between healthy and diseased 
people as both populations showed to have varying levels of anti-
staphylococcal antibody that do not correlate with health status of the people 
(Dryla et al., 2005). By comparing antibody concentration in our study with 
that of Dr Fattom study done in 1993, there was a similarity in antibody 
concentration of our patients with that of the pre-immunized patients of Dr 
Fattom ( Fattom et al., 1993) 
 	
 In this study the recognition of S. aureus by the immune system as 
measured by both anti-CP type 5 and anti-CP type 8 showed that ESRD 
patients have varying concentrations of circulating anti-CP5 and anti-CP8 
antibodies. The poor correlation between S. aureus nasal carriage and anti-
CP antibody levels indicates that this heterogeneity in the antibody level in 
the ESRD patients is independent of S. aureus nasal carriage. The variation 
in the antibody concentrations may have resulted from previous 
Staphylococcal infections, or non-specific antibody response that caused the 
variability in antibody level in both carrier and non-carrier ESRD patients.  
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